← Leaderboards
L. Jackson Roberts II
Vanderbilt University
$940,760
Attributed
$940,760
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $326.2K · FY2014–16$500K$375K$250K$125K$0
'14
'15
'16
Funding mix
By agency
NIH$940,760 · 1
By mechanism
N01$940,760 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- L Jackson Roberts$17,065,377
- James E Loyd$19,105,238
- Nancy Joan Brown$32,445,188
- Ivan M Robbins$2,964,589
- John D Imig$12,270,295
Others in their field
Top investigators on “Advanced Development”
- David Heimbrook · Leidos Biomedical Research, Inc.$625,894,719
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$331,630,794
- David H Reitze · University Of Florida$318,606,363
- Albert Lazzarini · California Institute Of Technology$317,303,333
Research focus
Advanced DevelopmentAntihypertensive AgentsBaseBlood VesselsCatalysisClinical TrialsContractsDiagnosticDrug CandidateEtiologyEvaluationFree RadicalsHypertensionHypertension TreatmentImmune SystemInflammationInnovationKetoaldehydeKidney Vascular StructureLeadMedicalModalityNational Heart, Lung, And Blood InstituteNeuraxis
Grant awards (3)
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): DEVELOPMENT OF GAMMA-KETOALDEHYDE SCAVENGERS FOR THE TREATMENT OF HYPERTENSION BASE PERIOD: NOVEMBER 15, 2013 - NOVEMBER$321,949
N01 · FY2016 · HL · contact PI
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): DEVELOPMENT OF GAMMA-KETOALDEHYDE SCAVENGERS FOR THE TREATMENT OF HYPERTENSION BASE PERIOD: NOVEMBER 15, 2013 - NOVEMBER$326,199
N01 · FY2015 · HL · contact PI
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): DEVELOPMENT OF GAMMA-KETOALDEHYDE SCAVENGERS FOR THE TREATMENT OF HYPERTENSION BASE PERIOD: NOVEMBER 15, 2013 - NOVEMBER$292,612
N01 · FY2014 · HL · contact PI